-

08:08:33 AM

Latest OPGN Stock Market News

OPGN - Opgen Inc

09/15/21 7:30 AM

Nasdaq : OPGN

clinical trial

OpGen Announces Data from Prospective Randomized Controlled Multicenter Clinical Study Using the Unyvero HPN Panel for Hospitalized Patients with Suspicion of Pneumonia

- Unyvero reduced the use of inappropriate antibiotic therapy by 45.1% - Unyvero shortened inappropriate antibiotic therapy by 39 hours, and reduced overall antibiotic therapy duration by 22.54% - 3 x higher probability of avoiding inappropriate antibiotic therapy in the patient group diagnosed by

RHEA-AI

neutral

08/12/21 4:15 PM

Nasdaq : OPGN

earnings

OpGen Reports Second Quarter 2021 Financial Results and Provides Business Update

RHEA-AI

neutral

08/04/21 4:30 PM

Nasdaq : OPGN

OpGen Announces the Cancellation of Adjourned Portion of Annual Meeting

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that it has determined to withdraw from stockholder

RHEA-AI

neutral

08/04/21 7:30 AM

Nasdaq : OPGN

earnings

OpGen to Provide Business Update and Financial Results for the Second Quarter 2021 on August 12th at 4:30 p.m. Eastern Time

OpGen, Inc. (NASDAQ: OPGN) (“OpGen” or “the Company”) announced today that the Company will provide a business update and report its second quarter 2021 financial results after the close of the U.S. financial markets on Thursday, August 12, 2021.

RHEA-AI

neutral

08/03/21 7:30 AM

Nasdaq : OPGN

OpGen Achieves Key Development Milestone in Unyvero A30 RQ Platform Program

RHEA-AI

neutral

07/07/21 4:30 PM

Nasdaq : OPGN

OpGen Announces Partial Adjournment of Annual Meeting

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular

RHEA-AI

neutral

06/30/21 7:30 AM

Nasdaq : OPGN

clinical trial

OpGen Announces Prospective Clinical Data from Unyvero LRT BAL and Acuitas AMR Gene Panel for Isolates Data Presented at World Microbe Forum

RHEA-AI

neutral

06/28/21 7:30 AM

Nasdaq : OPGN

OpGen Group Company Ares Genetics Presents R&D Pipeline Updates

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company

RHEA-AI

neutral

06/09/21 4:30 PM

Nasdaq : OPGN

OpGen Announces Partial Adjournment of Annual Meeting for Proposal 2 with All Other Proposals Passed

OpGen, Inc. (Nasdaq: OPGN, “OpGen” or the “Company”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that the Company conducted its 2021 annual

RHEA-AI

neutral

06/09/21 7:30 AM

Nasdaq : OPGN

OpGen Group Company Ares Genetics Presents at AWS and Twist Bioscience Webinars

OpGen, Inc. (Nasdaq: OPGN, “OpGen”), a precision medicine company harnessing the power of molecular diagnostics and informatics to help combat infectious disease, today announced that its subsidiary Ares Genetics, which strives to become a leader

RHEA-AI

neutral

1 2 3 4 5 6 Next

OPGN Data:

IndustryMedical Laboratories
Websitewww.opgen.com
CeoOliver Schacht
Security nameOpgen Inc
Issue typecs
SectorHealth Care and Social Assistance
Sic code8071
Employees102
Tags
- Health Technology
- Biotechnology
- Commercial Services
- Miscellaneous Commercial Services
- Health Care and Social Assistance
- Medical Laboratories
Address708 Quince Orchard Rd Ste 205
StateMaryland
CityGaithersburg
Zip20878-1793
CountryUS
Phone12408131260

OPGN Description:

OpGen, Inc. (Gaithersburg, MD, USA) is a precision medicine company harnessing the power of molecular diagnostics and bioinformatics to help combat infectious disease. Along with subsidiaries, Curetis GmbH and Ares Genetics GmbH, OpGen is developing and commercializing molecular microbiology solutions helping to guide clinicians with more rapid and actionable information about life threatening infections to improve patient outcomes, and decrease the spread of infections caused by multidrug-resistant microorganisms, or MDROs. OpGen's product portfolio includes Unyvero, Acuitas®AMR Gene Panel and Acuitas® Lighthouse, and the ARES Technology Platform including ARESdb, using NGS technology and AI-powered bioinformatics solutions for antibiotic response prediction.